Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 263 | 18% |
| 2020 | 6 | 178 | 22% |
| 2021 | 6 | 159 | 27% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nebraska; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 37 | 2,646+7.2%/yr | +7.2%/yr | 9.81.1× | 71% | 4,000 in 2030+7.1%/yr |
| Peripheral nerve stimulation & intrathecal pumps |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Ohio
| ≈ 250 |
| – |
| 2026 est. | ≈ 260 | – |
| 2022 | 5 | 175 | 31% |
| 2023 | 4 | 168 | 35% |
| 2024 | 5 | 200 | 37% |
| 2025 from claims | – | 250 202–293 | 37% |
| 2026 forecast | – | 256 200–321 | 37% |
| 2027 forecast | – | 260 193–344 | 37% |
| 2028 forecast | – | 265 187–366 | 38% |
| 2029 forecast | – | 270 183–386 | 38% |
| 2030 forecast | – | 274 180–407 | 38% |
In 2025, 35% hospital outpatient, 65% surgery center. The share outside the hospital has moved −8 pts since 2019.
| −4.8%/yr |
| 0.9 |
| 75% |
| 780 in 2030+1.7%/yr |
| Illinois | 20 | 692−5.2%/yr | −5.2%/yr | 0.5 | 47% | 820 in 2030+2.8%/yr |
| Missouri | 21 | 634−4.8%/yr | −4.8%/yr | 0.9 | 41% | 660 in 2030+0.5%/yr |
| Michigan | 13 | 535−8.6%/yr | −8.6%/yr | 0.6 | 51% | 480 in 2030−1.9%/yr |
| Kansas | 19 | 505−4.3%/yr | −4.3%/yr | 1.2 | 38% | 660 in 2030+4.7%/yr |
| Minnesota | 12 | 445−2.2%/yr | −2.2%/yr | 0.9 | 87% | 660 in 2030+6.9%/yr |
| Wisconsin | 10 | 363−4.6%/yr | −4.6%/yr | 0.6 | 50% | 420 in 2030+2.4%/yr |
| Iowa | 3 | 125−16%/yr | −16%/yr | 0.3 | 65% | 110 in 2030−1.9%/yr |
| South Dakota | 2 | 110−11%/yr | −11%/yr | 0.8 | 23% | 130 in 2030+3.2%/yr |
| 7 |
| 421+7.4%/yr |
| +7.4%/yr |
| 1.51.4× |
| 66% |
| 620 in 2030+6.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Pacira Pharmaceuticals leads with 23% of company spending on these surgeons in 2025, −22 pts on 2024.
In 2025, 8 companies reported engagement with Nebraska’s surgeons worth $111K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.